What is PTC Therapeutics?
Headquartered in South Plainfield, New Jersey, PTC Therapeutics is a specialized biopharmaceutical enterprise focused on the discovery, development, and commercialization of orally administered, small molecule drugs. The company is best known for its pioneering work in targeting post-transcriptional control processes, with its lead product, Translarna (ataluren), serving as a critical treatment for nonsense mutation Duchenne muscular dystrophy. By leveraging advanced scientific platforms, PTC Therapeutics continues to bridge the gap between complex genetic research and clinical application, maintaining a strong market position within the rare disease and orphan drug landscape.
How much funding has PTC Therapeutics raised?
PTC Therapeutics has raised a total of $2.5B across 22 funding rounds:
Series G
$30M
Grant
$1M
Series H
$60M
Stock Offering
$144.4M
Stock Offering
$118M
Stock Offering
$117.5M
Debt
$145.2M
Stock Offering
$117.9M
Multiple Rounds
$611.6M
Debt
$1B
Series G (2012): $30M with participation from Vulcan Ventures, HBM BioVentures, Delphi Ventures, The Column Group, Novo A/S, Celgene, and Credit Suisse First Boston
Grant (2012): $1M led by National Institute of Allergy and Infectious Diseases
Series H (2013): $60M supported by The Column Group, Jennison Associates, Adage Capital Management, Brookside Capital, Novo A/S, Longwood Fund, Vulcan Capital Management, Celgene, Credit Suisse First Boston, Delphi Ventures, and HBM Healthcare Investments
Stock Issuance/Offering (2013): $144.4M featuring Undisclosed
Stock Issuance/Offering (2014): $118M backed by Undisclosed
Stock Issuance/Offering (2014): $117.5M with participation from Undisclosed
Debt (2015): $145.2M led by Undisclosed
Stock Issuance/Offering (2018): $117.9M supported by Undisclosed
Stock Issuance/Offering (2019): $224.1M featuring Undisclosed
Debt (2019): $287.5M backed by Undisclosed
Stock Issuance/Offering (2019): $100M with participation from Undisclosed
Debt (2022): $1B led by Blackstone Credit
Key Investors in PTC Therapeutics
Novo A/S
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term investments in life sciences.
HBM Healthcare Investments
A publicly traded investment firm dedicated to the global healthcare sector, targeting growth opportunities driven by medical advancements and innovative therapies.
Delphi Ventures
A venture capital firm with two decades of experience in early-stage investing, specifically focused on medical devices and biotechnology innovation.
What's next for PTC Therapeutics?
With the recent strategic financing, PTC Therapeutics is well-positioned to accelerate its research and development initiatives, particularly as it navigates the complexities of late-stage clinical trials and global commercialization. The company's growth trajectory, supported by a history of institutional backing and strategic debt, suggests a focus on scaling its therapeutic portfolio and expanding its reach into new indications. As the firm continues to refine its drug discovery engine, the focus remains on long-term value creation through scientific excellence and the successful execution of its clinical pipeline, ensuring that its innovative treatments reach the patients who need them most.
See full PTC Therapeutics company page
